(Q30443910)

10 August 2017

Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study (English)

1 reference

10 August 2017

1 reference

1 reference

Diane R Mould

1

1 reference

10 August 2017

Gini F Fleming

series ordinal

2

1 reference

10 August 2017

Kathleen M Darcy

series ordinal

3

1 reference

10 August 2017

David Spriggs

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

62

1 reference

10 August 2017

1

1 reference

10 August 2017

56-70

1 reference

P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Pharmacokinetic profiles of doxorubicin in combination with taxanes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Measurement of fraction unbound paclitaxel in human plasma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Population pharmacodynamic model for ketorolac analgesia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

A size standard for pharmacokinetics.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Clinical toxicities encountered with paclitaxel (Taxol).

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Clinical pharmacokinetics of paclitaxel

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

20 June 2018

Free drug monitoring.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Problems in therapeutic drug monitoring: free drug level monitoring.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

A concordance correlation coefficient to evaluate reproducibility

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

A formula to estimate the approximate surface area if height and weight be known. 1916.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Is dose normalization to weight or body surface area useful in adults?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

A phase I trial of taxol given by a 6-hour intravenous infusion

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Prediction of creatinine clearance from serum creatinine

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Forecasting individual pharmacokinetics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

20 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

Assessment of actual significance levels for covariate effects in NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

Mechanism-based pharmacokinetic model for paclitaxel

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885077

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

26 November 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02718.X

Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer

21 January 2018

1 reference

12 December 2020

Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target

1 reference

12 December 2020

The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

1 reference

12 December 2020

Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein

1 reference

12 December 2020

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

12 December 2020

A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression

1 reference

12 December 2020

Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4

1 reference

12 December 2020

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

1 reference

12 December 2020

Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error

1 reference

12 December 2020

Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin

1 reference

12 December 2020

Pharmacokinetic models for the saturable distribution of paclitaxel

1 reference

12 December 2020

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

1 reference

12 December 2020

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

12 December 2020

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

12 December 2020

10.1111/J.1365-2125.2006.02718.X

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

16842379

1 reference